Harmony Biosciences purchased in October 2017 the exclusive rights to develop, register and commercialise pitolisant in the USA from the French company Bioprojet SCR, which developed the substance. There have already been a large number of successful clinical trials of pitolisant, and the compound is therefore approved for use in Europe and is marketed there under the trade name WAKIX^® for the treatment of narcolepsy in adults, both with and without cataplexy.